logo

For the Inventor, By the Inventor

New Brunswick, NJ, United States of America

Richard H Ebright

This inventor holds 38 USPTO granted patents and 4 published patent applications and 3 EPO patents, primarily in Antibacterial Agents. Top assignees: Rutgers, The State University of New Jersey, Provid Pharmaceuticals Inc., Bioarray Solutions Ltd.. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard H Ebright. Retrieved from https://idiyas.com/inventor/richard-h-ebright

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 38 

% Patents Active = 60.5

 

Average Co-Inventor Count = 2.0

ph-index = 5

Forward Citations = 241(Granted Patents)


Location History:

  • N. Brunswick, NJ (US) (1996)
  • Noth Brunswick, NJ (US) (2012)
  • North Brunswick, NJ (US) (2005 - 2014)
  • New Brunswick, NJ (US) (2014 - 2023)

Company Filing History:

goldMedal34 out of 1,502 
 
Rutgers, The State University of New Jersey
 patents
silverMedal2 out of 6 
 
Provid Pharmaceuticals Inc.
 patents
bronzeMedal1 out of 90 
 
Bioarray Solutions Ltd.
 patents
4. 3 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Antibacterial Agents
RNA Polymerase Inhibitors
High-Specificity Labeling
Pyronins
Phloroglucinols
Myxopyronin Derivatives
Bipartite Inhibitors
Chemical Probes
Nucleic Acid Sequences
Fluorescent Labeling
Dual-Targeted Inhibitors
Salinamide Derivatives
38 patents (USPTO):Explore Patents
1. 12209082 - Antibacterial agents: soluble salts and aqueous formulations of pyronins (2025-01-28),
2. 11685723 - Antibacterial agents: O-alkyl-deuterated pyronins (2023-06-27),
3. 11572337 - Antibacterial agents: arylalkylcarboxamido phloroglucinols (2023-02-07),
4. 11447502 - Antibacterial agents: dual-targeted RNA polymerase inhibitors (2022-09-20),
5. 10800725 - Arylpropionyl-triketone antibacterial agents (2020-10-13),
6. 10450292 - Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols (2019-10-22),
7. 10010619 - Bipartite inhibitors of bacterial RNA polymerase (2018-07-03),
8. 9945051 - Color-encoding and in-situ interrogation of matrix-coupled chemical compounds (2018-04-17),
9. 9919998 - Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides (2018-03-20),
10. 9839634 - Antibacterial agents: combination of a rifamycin and a switch region inhibitor (2017-12-12),
11. 9809626 - Antibacterial agents: salinamide derivatives (2017-11-07),
12. 9605028 - Antibacterial agents: salinamide derivatives (2017-03-28),
13. 9592221 - Antibacterial agents: aryl myxopyronin derivatives (2017-03-14),
14. 9517994 - Antibacterial agents: phloroglucinol derivatives (2016-12-13),
15. 9415112 - Bipartite inhibitors of bacterial RNA polymerase (2016-08-16),

Title: The Innovative Journey of Richard H. Ebright

Introduction: Richard H. Ebright, a distinguished inventor hailing from New Brunswick, NJ (US), has made significant contributions to the field of innovations and patents.

Latest Patents: Richard H. Ebright holds several patents in various technological domains, showcasing his continuous commitment to pioneering advancements in science and technology.

Career Highlights: Throughout his illustrious career, Richard H. Ebright has been at the forefront of groundbreaking inventions, revolutionizing industries and pushing the boundaries of what is possible.

Collaborations: Richard H. Ebright has collaborated with leading experts in the field, fostering a culture of innovation and knowledge-sharing that has led to remarkable advancements in technology.

Conclusion: Richard H. Ebright's dedication to innovation and his relentless pursuit of excellence have solidified his position as a trailblazer in the world of inventions and patents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…